摘要
Abstract
Non-selective β-blockers (NSBBs) can effectively reduce hepatic venous pressure gradient (HVPG),and are the first-line drugs for primary and secondary prevention of liver cirrhosis complicated by esophagogastric variceal bleeding.In addition,NSBBs can alleviate inflammatory response in patients with severe liver diseases.However,there are still controversies over the use of NSBBs in patients with liver cirrhosis complicated by intractable ascites,primary bacterial peritonitis,or kidney dysfunction.Therefore,NSBBs have a window period in the prevention of esophageal variceal bleeding with varying doses.Moreover,NSBBs have cardiogenic or non-cardiogenic side-effects,and thus side-effects should be closely monitored and the dose should be adjusted.This article reviews the latest research advances in NSBBs in preventing esophagogastric variceal bleeding.关键词
肝硬化/高血压,门静脉/非选择性β-受体阻滞剂/食管和胃静脉曲张/综述Key words
liver cirrhosis/hypertension, portal/non-selective-blockers/esophageal and gastric varices/review分类
医药卫生
